BCAB Stock Price, BioAtla, Inc. Quote, Chart

Market Summary

USD2.35+0.11

Market Closed

4.91%

BCAB Stock Price

View Fullscreen

BCAB RSI Chart

BCAB Valuation

Market Cap

113.0M

Price/Earnings (Trailing)

-0.92

Price/Sales (Trailing)

189.87

Price/Free Cashflow

-1.09

BCAB Price/Sales (Trailing)

BCAB Profitability

Return on Equity

-174.7%

Return on Assets

-103.18%

Free Cashflow Yield

-92.06%

BCAB Fundamentals

BCAB Revenue

Revenue (TTM)

590.0K

BCAB Earnings

Earnings (TTM)

-123.5M

Earnings Growth (Yr)

2.24%

Earnings Growth (Qtr)

19.2%

Breaking Down BCAB Revenue

Last 7 days

-7.1%

Last 30 days

0.9%

Last 90 days

10.3%

Trailing 12 Months

-31.5%

How does BCAB drawdown profile look like?

BCAB Financial Health

Current Ratio

4.11

BCAB Investor Care

Shares Dilution (1Y)

3.76%

Diluted EPS (TTM)

-2.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	590.0K	400.0K	250.0K
2020	4.0M	2.8M	1.6M	429.0K
2019	0	0	0	5.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioAtla, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	sievers eric	sold (taxes)	-1,967	3.44	-572	chief medical officer
Mar 31, 2024	smith scott andrew	sold (taxes)	-7,502	3.44	-2,181	-
Feb 29, 2024	smith scott andrew	sold (taxes)	-5,888	2.7	-2,181	-
Feb 29, 2024	sievers eric	sold (taxes)	-1,544	2.7	-572	chief medical officer
Feb 16, 2024	short jay m phd	acquired	-	-	417,000	chief executive officer
Feb 15, 2024	sievers eric	acquired	-	-	122,000	chief medical officer
Feb 15, 2024	vasquez christian	acquired	-	-	70,000	see remarks
Feb 15, 2024	waldron richard a	acquired	-	-	106,000	chief financial officer
Jan 31, 2024	sievers eric	sold (taxes)	-1,261	1.92	-657	chief medical officer
Jan 31, 2024	smith scott andrew	sold (taxes)	-4,187	1.92	-2,181	-

Which funds bought or sold BCAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.35	-4,000	5,000	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	new	-	1,720	1,720	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-58.00	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	180	180	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	unchanged	-	389,348	1,260,260	-%
Mar 12, 2024	PVG ASSET MANAGEMENT CORP	new	-	160,724	160,724	0.78%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-1.00	1,546,230	5,120,170	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	57.74	107,128	190,654	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	16,558	54,086	-%

Are Funds Buying or Selling BCAB?

Are funds buying BCAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCAB

No. of Funds

Unveiling BioAtla, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 16, 2024	soleus private equity fund i, l.p.	2.4%	1,134,601	SC 13D/A
Feb 14, 2024	tang capital partners lp	5.3%	2,524,076	SC 13G/A
Feb 09, 2024	short jay m phd	7.2%	3,458,190	SC 13G/A
Feb 06, 2024	acorn bioventures, l.p.	3.8%	1,824,918	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	2,884,014	SC 13G
Apr 27, 2023	acorn bioventures, l.p.	2.8%	1,314,039	SC 13G
Feb 27, 2023	short jay m phd	6.4%	2,982,036	SC 13G/A
Feb 14, 2023	cormorant asset management, lp	5.42%	2,499,250	SC 13G/A
Feb 14, 2023	tang capital partners lp	8.6%	3,124,076	SC 13G/A
Feb 09, 2023	vanguard group inc	4.19%	1,931,039	SC 13G/A

Recent SEC filings of BioAtla, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 16, 2024	SC 13D/A	13D - Major Acquisition
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to BioAtla, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

BioAtla, Inc. News

Latest updates

BioAtla, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-	-	-	250	-	150	190	-	-
Operating Expenses	-0.9%	23,488	23,695	30,710	16,455	8,165	4,710	1,198	-
S&GA Expenses	-1.4%	7,040	7,142	15,860	5,507	3,301	1,787	463	-
R&D Expenses	-0.6%	16,448	16,553	14,850	10,485	4,864	2,923	1,661	-
Interest Expenses	-	-	-	1.00	2.00	86.00	754	547	-
Net Income	-2.0%	-23,390	-22,930	-30,381	-16,395	-11,632	-6,222	-1,604	-
Net Income Margin	-7.9%	-161.70*	-149.84*	-113.56*	-	-	-	-	-
Free Cashflow	-64.6%	-20,949	-12,726	-13,545	-14,006	-15,462	-3,052	-3,814	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-20.9%	120	151	180	205	226	189	213	231	254	278	217	229	245
Current Assets	-21.1%	116	148	175	200	220	183	207	224	247	274	212	225	241
Cash Equivalents	-21.1%	111	141	169	193	216	178	202	219	245	270	208	221	239
Net PPE	-18.4%	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-13.5%	49.00	57.00	55.00	48.00	45.00	46.00	49.00	41.00	44.00	47.00	39.00	33.00	35.00
Current Liabilities	-20.4%	28.00	36.00	34.00	26.00	23.00	24.00	26.00	17.00	20.00	45.00	36.00	31.00	32.00
Shareholder's Equity	-25.4%	71.00	95.00	125	156	180	143	165	190	211	231	178	196	210
Retained Earnings	-6.9%	-416	-389	-356	-320	-292	-265	-239	-210	-186	-162	-140	-109	-90.92
Additional Paid-In Capital	0.6%	487	484	481	477	473	408	404	401	397	394	318	306	301
Shares Outstanding	0.4%	48.00	48.00	48.00	48.00	46.00	38.00	36.00	37.00	36.00	34.00	34.00	34.00	32.00
Float	-	-	-	91.00	-	-	-	69.00	-	-	-	1,000	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-9.4%	-29,922	-27,345	-24,094	-22,654	-24,347	-24,016	-16,921	-25,136	-20,949	-12,726	-13,545	-14,994	-14,006	-15,462	-3,052	-3,814	-
Share Based Compensation	-22.1%	2,738	3,517	3,675	3,614	3,501	3,588	3,842	3,632	3,810	4,366	12,298	4,643	3,022	-	-	-	-
Cashflow From Investing	68.0%	-8.00	-25.00	-15.00	-50.00	-31.00	-58.00	-166	-10.00	-89.00	-99.00	-235	-501	-395	-109	-66.00	-20.00	-
Cashflow From Financing	390.2%	119	-41.00	115	-116	61,765	-96.00	-51.00	-405	-3,908	75,141	190	-1,911	196,249	72,144	2,932	500	-

BCAB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development expense	$ 103,731	$ 79,347
General and administrative expense	25,956	28,793
Total operating expenses	129,687	108,140
Loss from operations	(129,687)	(108,140)
Other income (expense):
Interest income	6,312	1,648
Other income (expense)	(87)	10
Total other income (expense)	6,225	1,658
Consolidated net loss and comprehensive loss	$ (123,462)	$ (106,482)
Net loss per common share, basic	$ (2.58)	$ (2.74)
Net loss per common share, diluted	$ (2.58)	$ (2.74)
Weighted-average shares of common stock outstanding, basic	47,777,568	38,927,268
Weighted-average shares of common stock outstanding, diluted	47,777,568	38,927,268

BCAB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 111,471	$ 215,507
Prepaid expenses and other current assets	4,935	4,924
Total current assets	116,406	220,431
Property and equipment, net	1,603	2,728
Operating lease right-of-use-asset, net	1,495	2,423
Other assets	154	154
Total assets	119,658	225,736
Current liabilities:
Accounts payable and accrued expenses	26,720	21,610
Operating lease liabilities	1,624	1,521
Total current liabilities	28,344	23,131
Operating lease liabilities, less current portion	836	2,460
Liability to licensor	19,806	19,806
Total liabilities	48,986	45,397
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021	0	0
Common stock value	5	5
Additional paid-in capital	486,930	473,135
Accumulated deficit	(416,263)	(292,801)
Total stockholders' equity	70,672	180,339
Total liabilities and stockholders' equity	$ 119,658	$ 225,736

About BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

CEO	Dr. Jay M. Short Ph.D.
WEBSITE	bioatla.com
INDUSTRY	Biotechnology
EMPLOYEES	66

BioAtla, Inc. Frequently Asked Questions

What is the ticker symbol for BioAtla, Inc.? What does BCAB stand for in stocks?

BCAB is the stock ticker symbol of BioAtla, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioAtla, Inc. (BCAB)?

As of Wed Apr 24 2024, market cap of BioAtla, Inc. is 112.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCAB stock?

You can check BCAB's fair value in chart for subscribers.

What is the fair value of BCAB stock?

You can check BCAB's fair value in chart for subscribers. The fair value of BioAtla, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioAtla, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioAtla, Inc. a good stock to buy?

The fair value guage provides a quick view whether BCAB is over valued or under valued. Whether BioAtla, Inc. is cheap or expensive depends on the assumptions which impact BioAtla, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCAB.

What is BioAtla, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, BCAB's PE ratio (Price to Earnings) is -0.92 and Price to Sales (PS) ratio is 189.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCAB PE ratio will change depending on the future growth rate expectations of investors.